<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Famciclovir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Famciclovir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Famciclovir: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12461" href="/d/html/12461.html" rel="external">see "Famciclovir: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13294" href="/d/html/13294.html" rel="external">see "Famciclovir: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866869"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Famciclovir;</li>
<li>APO-Famciclovir;</li>
<li>Famvir;</li>
<li>PMS-Famciclovir;</li>
<li>SANDOZ Famciclovir [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F169877"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent</li></ul></div>
<div class="block doa drugH1Div" id="F169845"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc927598-72d2-4e9c-90f1-41398e5be5e9">Herpes simplex virus, mucocutaneous infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, mucocutaneous infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Genital:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompetent patients:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, initial episode (off-label use): <b>Oral:</b> 250 mg 3 times daily for 7 to 10 days; extend duration if lesion has not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, recurrent episode: <b>Oral: </b>1 g twice daily for 1 day<b> or </b>500 mg as a single dose, followed by 250 mg twice daily for 2 days<b> or </b>125 mg twice daily for 5 days. <b>Note:</b> Treatment is most effective when initiated during the prodrome or within 1 day of lesion onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Suppressive therapy (eg, for severe and/or frequent recurrences): <b>Oral:</b> 250 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompromised patients (including patients with HIV):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, initial (off-label use) or recurrent episode: <b>Oral:</b> 500 mg twice daily for 5 to 10 days; extend treatment duration if lesions have not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2021'])">Ref</a></span>). <b>Note:</b> Severe disease should be treated initially with IV acyclovir; may switch to famciclovir when lesions begin to regress and continue for at least 10 days total and until lesions have resolved completely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-HHS.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-HHS.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Suppressive therapy (eg, for severe and/or frequent recurrences) (off-label use): <b>Oral:</b> 500 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Orolabial:</b>
<b>Note:</b> Initiate therapy at earliest symptom.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompetent patients:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, initial infection (eg, gingivostomatitis):<b> Oral: </b>250 mg 3 times daily <b>or</b> 500 mg twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, recurrent infection (eg, cold sores): <b>Oral:</b> 1.5 g as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immunocompromised patients (including patients with HIV): </i></p>
<p style="text-indent:-2em;margin-left:8em;">Treatment, initial or recurrent infection: <b>Oral:</b> 500 mg twice daily for 5 to 10 days; extend treatment duration if lesions have not healed completely after 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-HHS.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-HHS.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Suppressive therapy (eg, for severe and/or frequent recurrences) (off-label use): <b>Oral: </b>500 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-HHS.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-HHS.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a97b74f2-593b-4b72-94fe-1d1f04a68f51">Herpes simplex virus, prevention in solid organ transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, prevention in solid organ transplant recipients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Herpes simplex virus–seropositive patients who do <b>not</b> require cytomegalovirus prophylaxis</i>: <b>Oral:</b> 500 mg twice daily for at least 1 month post-transplant; may consider resumption of prophylaxis during periods of lymphodepletion associated with treatment of rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e7bc6fa-f3f3-4346-982a-01ee6e4ad790">Herpes zoster, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster (shingles), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Initiate at earliest sign or symptom. Antiviral treatment is most effective ≤72 hours after rash onset but may be initiated &gt;72 hours in certain situations (eg, new lesions continue to appear); for immunocompromised patients, initiate treatment even if &gt;72 hours after symptom onset unless all lesions have crusted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10375341','lexi-content-ref-HHS.2021','lexi-content-ref-29746903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10375341','lexi-content-ref-HHS.2021','lexi-content-ref-29746903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute localized dermatomal lesion(s):</i>
<b>Oral:</b> 500 mg 3 times daily for 7 to 10 days; for slowly improving lesions, can extend therapy until resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-10375341','lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-10375341','lexi-content-ref-HHS.2022'])">Ref</a></span>). For select immunocompromised patients at high risk of dissemination (eg, recent transplant, graft-versus-host disease), some experts suggest regimens used for disseminated zoster (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17143845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17143845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated zoster (extensive cutaneous lesions or visceral involvement):</i>
<b>Oral:</b> Initial therapy with acyclovir IV may be switched to famciclovir 500 mg 3 times daily to complete a 10- to 14-day course when formation of new lesions has ceased and signs/symptoms of visceral infection are improving (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31162727','lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31162727','lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a4d8b31-1c06-48ee-b97e-c0c7b19c1f75">Varicella infection in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella infection (chickenpox) in patients with HIV (uncomplicated cases) (off-label use): Oral:</b> 500 mg 3 times daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2021'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991666"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Herpes zoster: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Administer 250 mg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer 250 mg after each dialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Recurrent genital herpes: Treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-day regimen:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours for 1 day</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to 39 mL/minute: Administer 500 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;20 mL/minute: Administer 250 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Administer 250 mg as a single dose after a dialysis session.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternatively the following recommendations have been made (Famvir Canadian product labeling):</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;20 mL/minute/1.73 m<sup>2</sup>: Administer 125 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Administer 125 mg every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Administer 125 mg after each dialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Recurrent genital herpes: Suppression:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥40 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to 39 mL/minute: Administer 125 mg every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Administer 125 mg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer 125 mg after each dialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Recurrent herpes labialis: Treatment (single-dose regimen):</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 40 to 59 mL/minute: Administer 750 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to 39 mL/minute: Administer 500 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Administer 250 mg as a single dose</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer 250 mg as a single dose after a dialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Recurrent orolabial/genital (mucocutaneous) herpes in patients with HIV:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥40 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Administer 250 mg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer 250 mg after each dialysis session.</p></div>
<div class="block doha drugH1Div" id="F50988970"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild-to-moderate impairment: No dosage adjustment is necessary</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment: No dosage adjustment provided in manufacturer’s labeling; has not been studied. However, a 44% decrease in the C<sub>max</sub> of penciclovir (active metabolite) was noted in patients with mild-to-moderate impairment; impaired conversion of famciclovir to penciclovir may affect efficacy.</p></div>
<div class="block doe drugH1Div" id="F169846"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F45503347"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13294" href="/d/html/13294.html" rel="external">see "Famciclovir: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2b01a83-a4d2-4d7a-80a1-c067cbf6fbe0">Herpes simplex virus, genital infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus (HSV), genital infection: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompetent patients:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial episode, treatment: Children weighing ≥45 kg and Adolescents: Oral: 250 mg 3 times daily for 7 to 10 days; treatment duration can be extended if healing is incomplete after 10 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Recurrent episode, treatment: Children weighing ≥45 kg and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2021'])">Ref</a></span>): <b>Note:</b> Initiate treatment within 1 day of lesion onset or during the prodrome that precedes some outbreaks.</p>
<p style="text-indent:-2em;margin-left:8em;">One-day regimen: Oral: 1,000 mg twice daily for 1 day.</p>
<p style="text-indent:-2em;margin-left:8em;">Two-day regimen: Oral: 500 mg once as a single dose, followed 12 hours later by 250 mg twice daily for 2 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Five-day regimen: Oral: 125 mg twice daily for 5 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Suppressive therapy: Children weighing ≥45 kg and Adolescents: Oral: 250 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompromised patients (including patients with HIV):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial or recurrent episodes, treatment: Adolescents: Oral: 500 mg twice daily for 5 to 10 days; extend treatment duration if lesions have not healed completely after 10 days. Consider treating initial episodes for at least 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2022','lexi-content-ref-27875039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2022','lexi-content-ref-27875039'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Suppressive therapy: Adolescents: Oral: 500 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-27875039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647','lexi-content-ref-34292926','lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1','lexi-content-ref-27875039'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96306a66-94e4-4129-a3ec-a291c736a69c">Herpes simplex virus, orolabial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes simplex virus, orolabial infection (cold sores):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without HIV: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Recurrent episodes, treatment: Adolescents: Oral: 1,500 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21178655','lexi-content-ref-Stanberry.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21178655','lexi-content-ref-Stanberry.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial or recurrent episodes, treatment: Adolescents: Oral: 500 mg twice daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Suppressive therapy: Adolescents: Oral: 500 mg twice daily. <b>Note:</b> Reassess need periodically (eg, annually) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="752ffd77-ac9c-44ef-a905-78db0fb226db">Herpes zoster in patients with HIV, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Herpes zoster (shingles) in patients with HIV, treatment </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute localized dermatomal lesion</i>: Adolescents: Oral: 500 mg 3 times daily for 7 to 10 days; for slowly improving lesions, can extend therapy until resolution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extensive cutaneous lesion or visceral involvement</i>: Adolescents: Oral step-down therapy following initial parenteral acyclovir when formation of new lesions has ceased and signs and symptoms of visceral varicella zoster virus infection are improving: Oral: 500 mg 3 times daily to complete a 10- to 14-day course.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="981d9340-3f68-42e2-ba68-b591f2048015">Varicella infection in patients with HIV, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella infection (chickenpox) in </b>
<b>patients with HIV (uncomplicated cases), treatment:</b> Limited data available: Adolescents: Oral: 500 mg 3 times daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130520"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations available; based on experience in adult patients; dosage adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51109822"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no pediatric specific recommendations available; experience in adults suggests no dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). A 44% decrease in the C<sub>max</sub> of penciclovir (active metabolite) was noted in adult patients with mild to moderate impairment; impaired conversion of famciclovir to penciclovir may affect efficacy.</p></div>
<div class="block adr drugH1Div" id="F169810"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (11% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (9% to 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2% to 4%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%), diarrhea (2% to 8%), flatulence (≤5%), vomiting (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (1%), neutropenia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (2%), increased serum bilirubin (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (≤5%), migraine (≤3%), paresthesia (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, cholestatic jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, hypersensitivity angiitis (Chou 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (Gales 1996), delirium, disorientation, dizziness, drowsiness, hallucination, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia (Gales 1996)</p></div>
<div class="block coi drugH1Div" id="F169823"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to famciclovir, penciclovir, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F169807"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. Acute renal failure has been reported with use of inappropriate high doses in patients with underlying renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Tablets contain lactose; do not use with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes.</p></div>
<div class="block foc drugH1Div" id="F169817"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F169803"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F169826"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Famciclovir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $5.81 - $6.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $6.32 - $6.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $12.69 - $13.95</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866870"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Famvir: 125 mg, 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p></div>
<div class="block adm drugH1Div" id="F9537092"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals.</p></div>
<div class="block admp drugH1Div" id="F52612805"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals</p></div>
<div class="block use drugH1Div" id="F169820"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">Treatment of acute herpes zoster (shingles) in immunocompetent patients; treatment and suppression of recurrent episodes of genital herpes in immunocompetent patients; treatment of herpes labialis (cold sores) in immunocompetent patients; treatment of recurrent orolabial/genital (mucocutaneous) herpes simplex in adult patients with HIV.</p></div>
<div class="block off-label drugH1Div" id="F45503346"><span class="drugH1">Use: Off-Label: Adult</span><p>Herpes simplex virus, prevention in solid organ transplant recipients; Varicella infection (chickenpox) in patients with HIV</p></div>
<div class="block mst drugH1Div" id="F6743664"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Famvir may be confused with Femara</p>
<p style="text-indent:-2em;margin-left:4em;">Famciclovir may be confused with acyclovir</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299311"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220317"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus Vaccine: Famciclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of famciclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of famciclovir for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoster Vaccine (Live/Attenuated): Famciclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F169839"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected. Management: Administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F169827"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome information following maternal use of famciclovir during pregnancy is limited (Pasternak 2010; Wilton 1998). One study observed an increased risk of gastroschisis following use of antiherpetic medications such as famciclovir during the first trimester to treat maternal genital herpes; this risk was also increased in the offspring of women with genital herpes not receiving treatment (Ahrens 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Famciclovir is approved for the treatment of genital herpes simplex virus (HSV)<i>. </i>Primary HSV infection during the first trimester may be associated with neonatal chorioretinitis, microcephaly, and skin lesions. The risk of perinatal transmission is greater when the primary infection occurs during pregnancy. Maternal treatment decreases duration and severity of disease and duration of viral shedding. However, if treatment is needed during pregnancy, agents other than famciclovir are recommended (ACOG 2020; CDC [Workowski 2021]).</p></div>
<div class="block brc drugH1Div" id="F169828"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if famciclovir is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Patients receiving treatment for herpetic lesions near or on the breast should not breastfeed (ACOG 2020). Patients with breast lesions can pump and discard milk to maintain milk supply until lesions are healed and breastfeeding can be resumed (D’Andrea 2019).</p></div>
<div class="block mop drugH1Div" id="F169815"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic CBC during long-term therapy; renal function</p></div>
<div class="block pha drugH1Div" id="F169806"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Famciclovir undergoes rapid biotransformation to the active compound, penciclovir (prodrug), which is phosphorylated by viral thymidine kinase in HSV-1, HSV-2, and VZV-infected cells to a monophosphate form; this is then converted to penciclovir triphosphate and competes with deoxyguanosine triphosphate to inhibit HSV-2 polymerase, therefore, herpes viral DNA synthesis/replication is selectively inhibited.</p></div>
<div class="block phk drugH1Div" id="F169822"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Food decreases maximum peak penciclovir concentration and delays time to penciclovir peak; AUC remains the same </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Healthy adults: Penciclovir: 1.08 ± 0.17 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Penciclovir: &lt;20%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Famciclovir is rapidly deacetylated and oxidized to penciclovir (active prodrug); <i>in vitro</i> data demonstrate that metabolism does not occur via CYP isoenzymes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Penciclovir: 77% ± 8%  </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Penciclovir: 2 to 4 hours; Prolonged in renal impairment:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">CrCl 40 to 59 mL/minute: ~3.4 hours</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">CrCl 20 to 39 mL/minute: ~6.2 hours, </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">CrCl &lt;20 mL/minute: ~13.4 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intracellular penciclovir triphosphate: HSV 1: 10 hours; HSV 2: 20 hours; VZV: 7 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Penciclovir: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (73% primarily as penciclovir); feces (27%) </p></div>
<div class="block phksp drugH1Div" id="F51154128"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: With CrCl 40 to 59 mL/minute, clearance is approximately 13 L/hour; CrCl 20 to 39 mL/minute, clearance is about approximately 4.2 L/hour; CrCl less than 20 mL/minute, clearance is approximately 1.6 L/hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Penciclovir C<sub>max</sub> decreased 44% and T<sub>max</sub> increased 0.75 hours in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean penciclovir AUC was 40% higher, and penciclovir renal clearance was 22% lower in elderly volunteers.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: AUC of penciclovir was approximately 9.3 mcg•h/mL and 11.1 mcg•h/mL in male and female volunteers, respectively, after a single 500 mg dose. Penciclovir renal clearance was 28.5 L/h and 21.8 L/h, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038615"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Famlogen | Famvir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Famciclovir Actavis | Famvir</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal famciclovir once | Aph famciclovir | Apo famciclovir | Auro famciclovir | Blooms the chemist famciclovir once | Chemists own favic for cold sore | Chemmart famciclovir | Elovax one dose | Ezovir | Ezovir cold sore relief | Famciclovir an | Famciclovir fbm | Famciclovir ga | Famciclovir generichealth | Famciclovir Sandoz | Famciclovir scp | Famlo | Famvir | Favic | Favir for cold sores | Pharmacy care famciclovir | Terry White Chemists Famciclovir | Terry white famciclovir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Famvir | Fanclomax | Penvir</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Famvir | Fan le | Hai zheng wei ke | Haizheng wei ke | Li zhu feng | Norkovir | Nuo ke</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Famvir | Famvir Zoster</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Famciclovir Teva | Famvir</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Famclovir | Famvir | Propencivir</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ancivin | Famciclovir Actavis | Famciclovir normon | Famciclovir pensa | Famciclovir Pharmagenus | Famciclovir stada | Famciclovir tecnigen | Famciclovir Teva | Famciclovir tevagen | Famvir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oravir</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Famcilet | Famcivar | Famvir | Flost | Zontir</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo famciclovir | Famvir | Pms famciclovir</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Famciclovir Teva | Famvir | Myclovear</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Famcimac | Famnova | Famtrex | Microvir | Penvir | Virax fc | Virovir</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Famciclovir M.G | Famvir | Macivir | Vilacir | Ziravir</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Famciclovir dsep | Famciclovir jg | Famciclovir kn | Famciclovir nichiiko | Famciclovir nippon zoki | Famciclovir pfizer | Famciclovir sawai | Famciclovir takata | Famciclovir towa | Famciclovir yd | Famvir</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Famvir | Penvir | Virafam</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anaclover | Bearclovir | Byclin | Bycro | Cl famciclovir | Clofam | Clovir | Disfosin | Fambiclo | Fambir | Famchair | Famci | Famci m | Famcical | Famcican | Famcicla | Famcicle | Famciclean | Famciclo | Famciclover | Famcico | Famcicol | Famcicool | Famcicra | Famcidrin | Famciem | Famcilovar | Famcina | Famcinal | Famcinex | Famcinova | Famcione | Famcipro | Famcir | Famcirac | Famciro | Famcirol | Famciron | Famcis | Famcit | Famcitech | Famciver | Famcivil | Famcivir | Famciz | Famcle | Famclear | Famcler | Famclo | Famclor | Famclovir | Famcrine | Famcure | Famdio | Famhere | Famicle | Famivir | Famlova | Famlovir | Famnova | Fampis | Famsna | Famster | Famsure | Famvicin | Famvicle | Famviclo | Famvics | Famvid | Famvina | Famvir | Famviro | Famvis | Famvital | Famylex | Favir | Femir | Fenvir | Herfam | Hufamci | Il yang famciclover | Ilyangbio famciclovir | J famci | Jw famciclovir | K famcier | Kingvir | Kukje famciclovir | Lofamci | Oravil | Pamcrova | Pamdiac | Pamicle | Pamses | Pamsirover | Pharma famciclovir | Samsung famciclovir | Withus famciclovir | Zosfam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Famciclovir Actavis | Famciclovir PCH | Famciclovir Sandoz | Famvir</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo famciclovir | Famvir</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Famclovir | Famvir | Famylex | Flovir | Viracure | Virovir</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Famacivir | Famciclovir Teva | Familar | Famvir | Favirox | Minaker</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo famciclovir | Famvir | Pms famciclovir</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Famvir | Virmol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Famvir</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Famvir | Viraxa | Virostat</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Penvir</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Famtrex | Famvir</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Penvir</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM; National Birth Defects Prevention Study. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. <i>Paediatr Perinat Epidemiol</i>. 2013;27(4):340-345. doi:10.1111/ppe.12064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/23772935/pubmed" id="23772935" target="_blank">23772935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8799682">
<a name="8799682"></a>Alrabiah FA, Sacks SL. New Antiherpesvirus Agents. Their Targets and Therapeutic Potential. <i>Drugs</i>. 1996; 52(1):17-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8799682/pubmed" id="8799682" target="_blank">8799682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference">
                  American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 220: Management of genital herpes in pregnancy. <i>Obstet Gynecol</i>. 2020;135(5):e193-e202. doi:10.1097/AOG.0000000000003840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/32332414/pubmed" id="32332414" target="_blank">32332414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21178655">
<a name="21178655"></a>Block SL, Yogev R, Waldmeier F, Hamed K. Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis. <i>Pediatr Infect Dis J</i>. 2011;30(6):525-528. doi:10.1097/INF.0b013e3182067cee<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/21178655/pubmed" id="21178655" target="_blank">21178655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162668">
<a name="8162668"></a>Boike SC, Pue MA, Freed MI. Pharmacokinetics of Famciclovir in Subjects With Varying Degrees of Renal Impairment. <i>Clin Pharmacol Ther</i>. 1994;55(4):418-426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8162668/pubmed" id="8162668" target="_blank">8162668</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Boyd MR, Safrin S, Kern ER. Penciclovir: A Review of Its Spectrum of Activity, Selectivity, and Cross Resistance Pattern. <i>Antivir Chem Chemother</i>. 1993;4:3-11.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22380582">
<a name="22380582"></a>Chou CY, Tsai HH, Cheng CJ, Lin YT, Wang KH. Famciclovir-induced leukocytoclastic vasculitis. <i>J Dermatol</i>. 2012;39(8):735-736. doi:10.1111/j.1346-8138.2011.01503.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/22380582/pubmed" id="22380582" target="_blank">22380582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10375341">
<a name="10375341"></a>Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. <i>Ann Intern Med</i>. 1999;130(11):922-932. doi:10.7326/0003-4819-130-11-199906010-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/10375341/pubmed" id="10375341" target="_blank">10375341</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  D'Andrea MA, Spatz DL. Maintaining breastfeeding during severe infant and maternal HSV-1 infection: a case report. <i>J Hum Lact</i>. 2019;35(4):737-741. doi:10.1177/0890334419830994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/30840531/pubmed" id="30840531" target="_blank">30840531</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Daniels S, Schentag JJ. Drug Interaction Studies and Safety of Famciclovir in Healthy Volunteers: A Review. <i>Antivir Chem Chemother.</i> 1993;4:57-64.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8407694">
<a name="8407694"></a>De Clercq E. Antivirals for the Treatment of Herpesvirus Infections. <i>J Antimicrob Chemother</i>. 1993;32(suppl A):121-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8407694/pubmed" id="8407694" target="_blank">8407694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17143845">
<a name="17143845"></a>Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. <i>Clin Infect Dis</i>. 2007;44(suppl 1):S1-S26. doi:10.1086/510206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/17143845/pubmed" id="17143845" target="_blank">17143845</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Famciclovir tablets [prescribing information]. Warren, NJ: Cipla USA Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  Famvir (famciclovir) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8781691">
<a name="8781691"></a>Gales BJ, Gales MA. Confusion and bradykinesia associated with famciclovir therapy for herpes zoster. <i>Am J Health Syst Pharm</i>. 1996;53(12):1454-1456. doi:10.1093/ajhp/53.12.1454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8781691/pubmed" id="8781691" target="_blank">8781691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8827396">
<a name="8827396"></a>Gill KS, Wood MJ. The Clinical Pharmacokinetics of Famciclovir. <i>Clin Pharmacokinet</i>. 1996;31(1):1-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8827396/pubmed" id="8827396" target="_blank">8827396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7537399">
<a name="7537399"></a>Goffin E, Horsmans Y, Pirson Y, et al. Acute Necrotico-Hemorrhagic Pancreatitis After Famciclovir Prescription. <i>Transplantation</i>. 1995;59(8):1218-1219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/7537399/pubmed" id="7537399" target="_blank">7537399</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hodge RA. Famciclovir and Penciclovir: The Mode of Action of Famciclovir Including Its Conversion to Penciclovir. <i>Antivir Chem Chemother</i>. 1993;4:67-84.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859647">
<a name="30859647"></a>Lee DH, Zuckerman RA; AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13526. doi:10.1111/ctr.13526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/30859647/pubmed" id="30859647" target="_blank">30859647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8876860">
<a name="8876860"></a>Luber AD and Flaherty JF Jr, “Famciclovir for Treatment of Herpesvirus Infections,” <i>Ann Pharmacother</i>, 1996, 30(9):978-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8876860/pubmed" id="8876860" target="_blank">8876860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20736469">
<a name="20736469"></a>Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. <i>JAMA</i>. 2010;304(8):859-866. doi:10.1001/jama.2010.1206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/20736469/pubmed" id="20736469" target="_blank">20736469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31162727">
<a name="31162727"></a>Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13622. doi:10.1111/ctr.13622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/31162727/pubmed" id="31162727" target="_blank">31162727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8521764">
<a name="8521764"></a>Perry CM, Wagstaff AJ. Famciclovir. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Herpesvirus Infections. <i>Drugs</i>. 1995;50(2):396-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8521764/pubmed" id="8521764" target="_blank">8521764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746903">
<a name="29746903"></a>Pott Junior H, de Oliveira MFB, Gambero S, Amazonas RB. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. <i>Int J Infect Dis</i>. 2018;72:11-15. doi:10.1016/j.ijid.2018.04.4324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/29746903/pubmed" id="29746903" target="_blank">29746903</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pue MA, Benet LZ. Pharmacokinetics of Famciclovir in Man. <i>Antivir Chem Chemother</i>. 1993;4(suppl 1):47-55.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8840414">
<a name="8840414"></a>Sacks SL. Genital Herpes Simplex Virus and Its Treatment Focus on Famciclovir. <i>Semin Dermatol.</i> 1996;15(2)(suppl 1):32-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8840414/pubmed" id="8840414" target="_blank">8840414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16781291">
<a name="16781291"></a>Spruance SL, Bodsworth N, Resnick H, et al, “Single-Dose, Patient-Initiated Famciclovir: A Randomized, Double-Blind, Placebo-Controlled Trial for Episodic Treatment of Herpes Labialis,” <i>J Am Acad Dermatol</i>, 2006, 55(1):47-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/16781291/pubmed" id="16781291" target="_blank">16781291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stanberry.1">
<a name="Stanberry.1"></a>Stanberry LR. Herpes simplex virus. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 279.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7778840">
<a name="7778840"></a>Tyring SK, Barbarash RA, Nahlik JE, et al. Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia. <i>Ann Intern Med</i>. 1995;123(2):89-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/7778840/pubmed" id="7778840" target="_blank">7778840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8840413">
<a name="8840413"></a>Tyring SK. Efficacy of Famciclovir in the Treatment of Herpes Zoster. <i>Semin Dermatol</i>. 1996;15(2)(suppl 1):27-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/8840413/pubmed" id="8840413" target="_blank">8840413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed September 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2021">
<a name="HHS.2021"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://www.idsociety.org/practice-guideline/prevention-and-treatment-of-opportunistic-infections-among-adults-and-adolescents/. Accessed September 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Children with and Exposed to HIV. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines</a>. Updated September 2, 2022. Accessed January 3, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.2021">
<a name="Wald.2021"></a>Wald A, Johnston C. Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27875039">
<a name="27875039"></a>
<i>WHO Guidelines for the Treatment of Genital Herpes Simplex Virus</i>. Geneva: World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/27875039/pubmed" id="27875039" target="_blank">27875039</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. <i>Br J Obstet Gynaecol</i>. 1998;105(8):882-889. doi:10.1111/j.1471-0528.1998.tb10234.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/9746382/pubmed" id="9746382" target="_blank">9746382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/famciclovir-drug-information/abstract-text/26042815 /pubmed" id="26042815 " target="_blank">26042815 </a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8435 Version 267.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
